177lu-rad204
MSI-High
Radiopharm Theranostics, LtdradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the MSI-High cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Obinutuzumab Simcha IL-18, Inc. | Phase 1/2 | CC |
Epirubicin Simcha IL-18, Inc. | Phase 1/2 | CC |
Pembrolizumab Simcha IL-18, Inc. | Phase 1/2 | CC |
Alintegimod 7 Hills Pharma, LLC | Phase 1/2 | CC |
Interleukin 18 (recombinant human mutein clone ST-067) Simcha IL-18, Inc. | Phase 1/2 | CC |
Nivolumab 7 Hills Pharma, LLC | Phase 1/2 | CC |
Ipilimumab 7 Hills Pharma, LLC | Phase 1/2 | CC |
Cyclophosphamide Simcha IL-18, Inc. | Phase 1/2 | CC |
Same molecule, other indications
177lu-rad204 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →